Vaney Capetillo

Experienced Clinical Research Coordinator with a strong background in study startup, regulatory maintenance, protocol visit execution, and clinical trial coordination. Proven ability to manage a portfolio of 20+ clinical research studies across Ophthalmology, Pediatric Endocrinology, and Oncology while maintaining attention to detail, regulatory compliance, and study requirements. Resourceful problem-solver committed to advancing clinical research and taking on greater responsibility in the field.

• Portrait drawing
• Acrylic painting
• Guitar
• Piano

• A Randomized, Single-Masked, Active-Controlled, Parallel-Group Evaluation of Safety and the Local Anesthetic Effect of Articaine Sterile Topical Ophthalmic Solution (AG-920) in a Pediatric Population
• A Phase 1/2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults with Neovascular (Wet) Age-Related Macular Degeneration
• A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of 0.25% Reproxalap Ophthalmic Solution in Subjects with Dry Eye Disease
• Open-label, Multiple Dose, Dose Escalation Study to Evaluate the Safety/Tolerability and EfZicacy of EA-2353 in Subjects with Retinosis Pigmentosa
• A Phase 2, Open Label Multicenter Clinical Trial to Evaluate the Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects with Stargardt Disease [STARLIGHT]
• Ophthalmic Assessments of Signs and Symptoms of Dry Eye in Patients Suffering from Self-Reported or Clinician-Diagnosed Dry Eye Disease
• A Phase 3 Study Evaluating the Safety and EfZicacy of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dry Eye Disease (COMET-2)
• A Multicenter, Open-Labeled, Phase 2A Study Evaluating the Safety, Tolerability, and EfZicacy of Intravitreal AG-73305 In Patients with Diabetic Macular Edema
• Dose ascending safety, tolerability, and proof of concept double masked, placebo controlled, randomized study to evaluate the use of ANXV (human recombinant Annexin A5) in the treatment of subjects with recently diagnosed Retinal Vein Occlusion
• A Phase 1 Study of the Safety, Pharmacokinetics, and Exploratory EfZicacy of Periocular Administration of AIV007 Gel Suspension in Subjects with Macular Edema Secondary to Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
• A Randomized, Open-label, Parallel-group, Multi-center Phase 2a Study to Evaluate the EfZicacy and Safety of CU06- 1004 for 12 Weeks in Patients with Diabetic Macular Edema (DME)
• A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to AZlibercept in Subjects with Wet AMD
• OTT166-201 A Phase 2 Randomized, Double-Masked, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and EfZicacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR)
• A Multi-Center, Randomized, Double-Masked Phase 2 Study to Assess Safety and EfZicacy of ADVM-022 (AAV.7m8-aZlibercept) in Anti-VEGF Treatment-Experienced Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD) [LUNA]
• A Phase 2 randomized, placebo-controlled, double-masked proof-of-concept study to investigate the efZicacy and safety of runcaiguat (BAY 1101042) in patients with moderately severe to severe non- proliferative diabetic retinopathy
• A Prospective Multi-Center Observational Study to assess the reliability and validity of the Multi- Luminate YMobility Test (MLYMT)
• A Phase 2, Randomized, Sham-Controlled, Single-Masked, DoseRanging, Multi-Center Study to Assess the Safety and EfZicacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects with Maculaoff Rhgematogenous Retinal Detachment
• A Multi-Center, Randomized, Parallel-Group, Phase 2, Masked, Three-Arm Trial to Compare Safety, Tolerability, EfZicacy, and Durability of Two Dose Levels of Suprachoroidal Sustained-Release OXU-001 (Dexamethasone Microspheres; DEXAspheres @) Using the Oxulumis@ Illuminated Microcatheterization Device Compared with Intravitreal Dexamethasone Implant (OZURDEX@) in Subjects with Diabetic Macular Edema (OXEYE)
• A Randomized, Double-Masked, Placebo-Controlled, Parallel-Arm Study to Evaluate the EfZicacy and Safety of RZ402 in Participants with Diabetic Macular Edema (DME) RZ402-201
• Phase 2 Spectra study to evaluate the safety and efZicacy of OPL-0401 in patients with diabetic retinopathy
• Phase 4 Study of YUTIQ (Zluocinolone acetonide intravitreal implant) 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis (Intracocular Inflammation) Study
• A prospective, single-arm, non-comparative, open-label, monocular, post approval study to assess safety and device performance of the Vista Vitrectomy Probe during vitrectomy surgery.
• Treat & Extend versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial
• A Phase 3 study to evaluate the efZicacy and safety of pegcetacoplan (APL-2) in patients with GA secondary to age-related macular degeneration
• An open-label extension study evaluating the long-term safety and efZicacy of pegcetacoplan (APL-2) in adults with GA secondary to age-related macular degeneration (AMD)
• ALLIANCE A211901 REACHING RURAL CANCER SURVIVORS WHO SMOKE USING TEXT-BASED CESSATION INTERVENTIONS
• NRG-G1008: COLON ADJUVANT CHEMOTHERAPY BASED ON EVALUATION OF RESIDUAL DISEASE (CIRCULATE-NORTH AMERICA)
• S2010, A RANDOMIZED PHASE III TRIAL COMPARING ACTIVE SYMPTOM MONITORING PLUS PATIENT EDUCATION VERSUS PATIENT EDUCATION ALONE TO IMPROVE PERSISTENCE WITH ENDOCRINE THERAPY IN YOUNG WOMEN WITH STAGE I-III BREAST CANCER (ASPEN)
• S2013, IMMUNE CHECKPOINT INHIBITOR TOXICITY (I-CHECKIT): A PROSPECTIVE OBSERVATIONAL STUDY
• TITLE PAGE S2205, ICE COMPRESS: RANDOMIZED TRIAL OF LIMB CRYOCOMPRESSION VERSUS CONTINUOUS COMPRESSION VERSUS LOW CYCLIC COMPRESSION FOR THE PREVENTION OF TAXANE-INDUCED PERIPHERAL NEUROPATHY
• RANDOMIZED, OPEN-LABEL STUDY OF THE BRIA-IMT REGIMEN AND CHECK POINT INHIBITOR VS PHYSICIAN'S CHOICE IN ADVANCED METASTATIC BREAST CANCER (BRIA-ABC)
• ORACLE: Observation of ResiduAl Cancer with Liquid biopsy Evaluation
• Randomized, Open-label Study of HLX10 plus Chemotherapy (CarboplatinEtoposide) in comparison with Atezolizumab plus Chemotherapy in Previously Untreated US Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ASTRIDE)
• A Phase 1b/2 Multicenter, Open-label Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Participants with Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
• THE WISDOM STUDY (WOMEN INFORMED TO SCREEN DEPENDING ON MEASURES OF RISK)
• Pfizer Registry of Outcomes in Growth hormone RESearch (PROGRES): A multi country, non-interventional prospective cohort study among patients with human growth hormone (hGH) treatments under routine clinical care